No SDB (n=96) | SDB (n=77) | p Value | |
Age (years) | 71.9 (59.4–77.6) | 66.7 (57.1–75.0) | 0.08 |
Men (n, %) | 81 (84) | 67 (87) | 0.67 |
BMI (kg/m2) | 27.4 (24.8–31.6) | 30.8 (27.8–35.4) | <0.001 |
Neck size (cm) | 39.0 (37.0–41.0) | 42.0 (39.5–43.0) | <0.001 |
Waist/hip ratio | 1.01 (0.96–1.05) | 1.03 (0.99–1.07) | 0.04 |
Diabetes (n, %) | 22 (23) | 22 (29) | 0.48 |
COPD/asthma (n, %) | 27 (28) | 7 (9) | 0.002 |
Ischaemic cardiomyopathy (n, %) | 54 (56) | 35 (46) | 0.17 |
β blocker therapy (n, %) | 62 (65) | 64 (83) | 0.009 |
ACEI/ARB therapy (n, %) | 87 (91) | 70 (91) | 1.0 |
Atrial fibrillation (n, %) | 26 (27) | 26 (34) | 0.41 |
Cardiac pacing (n, %) | 25 (26) | 26 (34) | 0.32 |
NYHA classification (I/II/III/IV) | 12/64/20/0 | 12/46/17/2 | 0.37 |
BNP (pg/ml) | 128 (69–201) | 107 (42–322) | 0.97 |
Left ventricle ejection fraction (%) | 40 (28–58) | 43 (32–58) | 0.76 |
Data are presented as median (IQR), or number (%) of patients.
ACEI/ARB, ACE inhibitor or angiotensin receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; SDB, sleep-disordered breathing.